

# Oral Presentations at 2018 ASH Annual Meeting

Presentation	Presenter	Time	Location
Aggressive Lymphomas	David M Weinstock, MD	7:30 – 9:00 a.m.	San Diego Convention Center, Hall AB
Approach to the Treatment of the Older, Unfit Patient With Myeloma: From Diagnosis to Relapse	Kenneth C. Anderson, MD	7:30 – 9:00 a.m.	San Diego Convention Center, Ballroom 20A
Epigenetic and Genomic Determinants in Cancer Immunotherapy	Julie-Aurore Losman, MD, PhD; W. Nicholas Haining, BM, BCh*	7:30 – 9:00 a.m.	San Diego Convention Center, Room 6F
55 Deciphering Clonal Evolution and Dissemination of Multiple Myeloma Cells In Vivo	Yujia Shen, PhD	7:30 a.m.	Marriott Marquis San Diego Marina, Grand Ballroom 7
SCI-16 Chromatin State and Immunotherapy	W. Nicholas Haining, BM, BCh*	7:30 – 9:00 a.m.	San Diego Convention Center, Room 6F
39 Targeted Inhibition of PI3K $\hat{\pm}/\hat{\pm}$ Is Synergistic with BCL-2 Blockade in Genetically Defined Subtypes of DLBCL	Kamil Bojarczuk, PhD	8:00 a.m.	San Diego Convention Center, Room 28D
57 In Vivo Modeling of Clonal Competition Using CRISPR-Based Gene Editing Reveals Novel Fitness Variables in Multiple Myeloma	Yujia Shen, PhD	8:00 a.m.	Marriott Marquis San Diego Marina, Grand Ballroom 7
40 A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTKCys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88	Guang Yang, PhD	8:15 a.m.	San Diego Convention Center, Room 28D
60 Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma	Tommaso Perini, MD	8:45 a.m.	Marriott Marquis San Diego Marina, Grand Ballroom 7
Relapsed CLL: Sequencing, Combinations, and Novel Agents	Jennifer R. Brown, MD, PhD	9:30 – 11:00 a.m.	San Diego Convention Center, Hall AB
Targeting Epigenetic Regulation in Myeloma	Irene M. Ghobrial, MD	9:30 – 11:00 a.m.	San Diego Convention Center, Room 11B
92 Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity	Caron A. Jacobson, MD	9:45 a.m.	Marriott Marquis San Diego Marina, Pacific Ballroom 20
Treating Myelodysplastic Syndromes: From Clonal Hematopoiesis to Almost Acute Myeloid Leukemia	David P. Steensma, MD, FACP	11:15 a.m. – 12:15 p.m.	Hilton San Diego Bayfront, Aqua Salon AB
145 Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience	Reid W. Merryman, MD	12:00 – 1:30 p.m.	Marriott Marquis San Diego Marina, Pacific Ballroom 20,

## Oral Presentations at 2018 ASH Annual Meeting

Presentation	Presenter	Time	Location
154 Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma	Irene M. Ghobrial, MD	12:45 p.m.	Marriott Marquis San Diego Marina, Grand Ballroom 7
150 Progression Risk-Based Classification of Asymptomatic Waldenström Macroglobulinemia	Mark Bustoros, MD	1:15 p.m.	Marriott Marquis San Diego Marina, Pacific Ballroom 20
Special Symposium on Quality	Gregory A. Abel, MD, MPH	2:00 – 3:30 p.m.	San Diego Convention Center, Room 11B
Approach to the Treatment of the Older, Unfit Patient With Myeloma: From Diagnosis to Relapse	Kenneth C. Anderson, MD	2:00 – 3:30 p.m.	San Diego Convention Center, Ballroom 20A
189 Functional Genomic Landscape of Genes with Recurrent Mutations in Multiple Myeloma	Ricardo De Matos Simoes, PhD	2:30 p.m.	Marriott Marquis San Diego Marina, Grand Ballroom 7
190 Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma	Mehmet Kemal Samur, PhD	2:45 p.m.	Marriott Marquis San Diego Marina, Grand Ballroom 7
How CHIP Flips Into MDS	David P. Steensma, MD, FACP	4:00 – 5:30 p.m.	San Diego Convention Center, Room 6A
261 Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium	Yana Pikman, MD*	4:30 p.m.	San Diego Convention Center, Room 7B
244 Plasmacytoid Dendritic Cells Trigger Contact-Dependent Tumor Promoting Genetic Alterations in Multiple Myeloma Cells	Arghya Ray, PhD	4:45 p.m.	Marriott Marquis San Diego Marina, Grand Ballroom 7
263 Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies	Sara Morrow, BA	5:00 p.m.	San Diego Convention Center, Room 7B
228 Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies	Philippe Armand, MD, PhD	5:15 p.m.	Marriott Marquis San Diego Marina, Pacific Ballroom 20